That is how i understood Nader's comment. the 127 patient enrollment is just a number as of yesterday, the peek at the data for the severe trial would be what can be seen at the time, no matter the # of patients. I think Nader was expecting the FDA to look art the M2M trail data and likely ask how the severe trial is looking to see if the same MOA is happening. The FDA really divided up the trials because many other drug trials were very specific in what stage Covid is in for the drug to work, or on what symtoms of Covid whatever drug might work on. No other drug is like Leronlimab, the others tackle parts of Covid and from their trial we can see that Covid needs to be handled completely and not just for each stage or symptom. The data from M2M and severe will likely paint a picture of Covid and Leronlimab together, The FDA will hopefully see this and approve Leronlimab for Covid at any stage, not just to the trial protocol confines